Skip to content

Gore Tex Implants in the Treatment of Atrophic Rhinitis

Gore Tex Implants in the Treatment of Atrophic Rhinitis

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00832403
Acronym
RA
Enrollment
5
Registered
2009-01-30
Start date
2006-11-30
Completion date
Unknown
Last updated
2009-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Rhinitis

Keywords

atrophic rhinitis, implants, Polytetrafluoroethylene

Brief summary

This is a retrospective study, involving patients with atrophic rhinitis, that underwent Gore tex® implants in the nasal fossa. The Fetid Rhinitis or Atrophic Ozena is a chronic illness characterized by yellowish secretion in the initial phase and the other phases with fetid crusts and atrophy of the mucous bone covering. Diverse theories exist that try to explain the appearance of this pathology, such as: hereditary factors, immunological alterations, viral infection and nutritional lack. Currently, its etiology remains unknown. As there isn't any ideal treatment already established, this technique improves the options of treatment. All patients have improved after the procedure.

Detailed description

Data about 5 patients that underwent surgery to implant polytetrafluoroethylene in the nasal fossa was collect. The symptoms and complications were described.

Interventions

OTHERimplants of polytetrafluoroethylene in tha nasal fossa

surgical implants of polytetrafluoroethylene in the nasal fossa

Sponsors

Hospital Felicio Rocho
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Symptoms of atrophic rhinitis, with previous clinical treatment without good results

Exclusion criteria

* Patients with mental illness

Design outcomes

Primary

MeasureTime frame
improvement of fetid crusts and atrophy of the mucous bone coveringafter surgery recovery

Secondary

MeasureTime frame
lack of side effects such as infectionafter the treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026